Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer

Abd El Halim Mohamed Abu-Hamar; Saleh Mansour; Mohamed El Shebiney; Naser Mohamed Abd El Bary; Emad Sadaka; Alaa Maria

首页> 外文期刊>Hematology/Oncology and Stem Cell Therapy >Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer

【24h】

Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer

机译：多西紫杉醇每三周加泼尼松治疗激素难治性转移性前列腺癌患者的生存期较差

获取原文

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Hematology/Oncology and Stem Cell Therapy》 |2010年第3期|共7页
作者
Abd El Halim Mohamed Abu-Hamar; Saleh Mansour; Mohamed El Shebiney; Naser Mohamed Abd El Bary; Emad Sadaka; Alaa Maria;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类一般性问题;
关键词

相似文献

外文文献
中文文献
专利

1. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. [J] . Saad F, Ruether D, Ernst S, BJU international . 2008,第5期

机译：加拿大Uro-Oncology Group多中心紫杉醇II期研究每3周对强的松转移性激素难治性前列腺癌的男性进行泼尼松治疗，该患者在米托蒽醌/泼尼松治疗后进展。
2. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. [J] . Oudard S, Banu E, Beuzeboc P, Journal of Clinical Oncology . 2005,第15期

机译：多中心紫杉醇，雌莫司汀和泼尼松与米托蒽醌加泼尼松两种方案治疗转移性激素难治性前列腺癌的多中心随机II期研究。
3. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. [J] . Machiels JP, Mazzeo F, Clausse M, Journal of Clinical Oncology . 2008,第32期

机译：比较多西他赛，雌莫司汀和泼尼松与多西他赛和泼尼松治疗转移性激素难治性前列腺癌的前瞻性随机研究。
4. Identification of Circulating Pluripotent Cancer Stem Cells in the Blood of Prostate Cancer Patients for the Diagnosis of Metastatic Cancer [C] . Anette Claudia Schafer, Yawen Ju, Youngbin Tak, International Molecular Medicine Tri-Conference. . 2016

机译：鉴定前列腺癌患者血液中循环多能癌症干细胞诊断转移性癌症
5. The Impact of Heterogeneity of Treatment Effect on Survival, Cost Effectiveness, and Coverage of Androgen Deprivation Therapy in Metastatic Prostate Cancer [D] . Aly, Abdalla 2015

机译：异质性对转移性前列腺癌生存率，成本效益和雄激素剥夺疗法覆盖率的影响
6. Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients [O] . G Bousquet, J Alexandre, C Le Tourneau, 2011

机译：BIBF 1120与多西紫杉醇和泼尼松治疗转移性化学原初激素难治性前列腺癌的I期研究
7. Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer [O] . Mohamed Abu-Hamar Abd El Halim, Mansour Saleh, El Shebiney Mohamed, 2010

机译：多西紫杉醇每三周加用泼尼松治疗激素难治性转移性前列腺癌患者的生存期较差

Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer

著录项

引文网络

相似文献

相关主题

期刊订阅